Treprostinil Palmitil for Pulmonary Arterial Hypertension

(PALM-PAH Trial)

This trial tests an inhalation powder called Treprostinil Palmitil to determine if it can help people with pulmonary arterial hypertension (PAH) improve their exercise capacity. PAH causes higher-than-normal blood pressure in the lungs, making physical activity difficult. Participants must have had a PAH diagnosis for at least three months, experience difficulty with physical activities, and be on stable PAH medication. The study compares Treprostinil Palmitil to a placebo over 24 weeks to assess its effectiveness. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial requires participants to stay on their current PAH medications, which must be stable for a certain period before joining the study. You should not stop taking your current medications if you are participating in this trial.

A previous study showed that treprostinil palmitil inhalation powder (TPIP) demonstrated promising safety results for people with pulmonary arterial hypertension (PAH). Research indicates that patients tolerated TPIP well at the tested doses. Many patients found the treatment easier to manage with gradual dose increases, which helped reduce side effects. Studies also show that TPIP absorbs predictably in the body, ensuring consistent effects across different patients. These findings suggest TPIP is generally safe for use in humans, though individual experiences may vary.¹²³⁴⁵

Researchers are excited about Treprostinil Palmitil Inhalation Powder because it offers a unique inhalation delivery method for treating pulmonary arterial hypertension (PAH). Unlike standard oral or injectable treatments like endothelin receptor antagonists or phosphodiesterase-5 inhibitors, this treatment delivers the medication directly to the lungs, potentially enhancing its effectiveness while minimizing systemic side effects. Additionally, Treprostinil Palmitil is a prodrug that is metabolized into treprostinil, which is already known to help dilate blood vessels in the lungs and improve blood flow, but with the potential for more targeted action and improved patient convenience.

This trial will compare Treprostinil Palmitil Inhalation Powder (TPIP) with a placebo for treating pulmonary arterial hypertension (PAH). Studies have shown that TPIP reduces lung blood vessel resistance by 35% compared to a placebo after 16 weeks. This reduction lowers pressure in the lung blood vessels, easing the heart's effort to pump blood. TPIP is designed to remain in the lungs longer, providing all-day effectiveness with a single dose. These findings suggest that TPIP could help people with PAH exercise more easily and improve overall heart function.¹⁴⁵⁶⁷